201 related articles for article (PubMed ID: 22438257)
1. Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ.
Godfrey R; Arora D; Bauer R; Stopp S; Müller JP; Heinrich T; Böhmer SA; Dagnell M; Schnetzke U; Scholl S; Östman A; Böhmer FD
Blood; 2012 May; 119(19):4499-511. PubMed ID: 22438257
[TBL] [Abstract][Full Text] [Related]
2. Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling.
Arora D; Stopp S; Böhmer SA; Schons J; Godfrey R; Masson K; Razumovskaya E; Rönnstrand L; Tänzer S; Bauer R; Böhmer FD; Müller JP
J Biol Chem; 2011 Apr; 286(13):10918-29. PubMed ID: 21262971
[TBL] [Abstract][Full Text] [Related]
3. NOX-driven ROS formation in cell transformation of FLT3-ITD-positive AML.
Jayavelu AK; Moloney JN; Böhmer FD; Cotter TG
Exp Hematol; 2016 Dec; 44(12):1113-1122. PubMed ID: 27666490
[TBL] [Abstract][Full Text] [Related]
4. NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.
Jayavelu AK; Müller JP; Bauer R; Böhmer SA; Lässig J; Cerny-Reiterer S; Sperr WR; Valent P; Maurer B; Moriggl R; Schröder K; Shah AM; Fischer M; Scholl S; Barth J; Oellerich T; Berg T; Serve H; Frey S; Fischer T; Heidel FH; Böhmer FD
Leukemia; 2016 Feb; 30(2):473-83. PubMed ID: 26308771
[TBL] [Abstract][Full Text] [Related]
5. NADPH oxidase-generated hydrogen peroxide induces DNA damage in mutant FLT3-expressing leukemia cells.
Stanicka J; Russell EG; Woolley JF; Cotter TG
J Biol Chem; 2015 Apr; 290(15):9348-61. PubMed ID: 25697362
[TBL] [Abstract][Full Text] [Related]
6. Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias.
Zorko NA; Bernot KM; Whitman SP; Siebenaler RF; Ahmed EH; Marcucci GG; Yanes DA; McConnell KK; Mao C; Kalu C; Zhang X; Jarjoura D; Dorrance AM; Heerema NA; Lee BH; Huang G; Marcucci G; Caligiuri MA
Blood; 2012 Aug; 120(5):1130-6. PubMed ID: 22674806
[TBL] [Abstract][Full Text] [Related]
7. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
Marhäll A; Heidel F; Fischer T; Rönnstrand L
Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
[TBL] [Abstract][Full Text] [Related]
8. Subcellular localization of the FLT3-ITD oncogene plays a significant role in the production of NOX- and p22
Moloney JN; Stanicka J; Cotter TG
Leuk Res; 2017 Jan; 52():34-42. PubMed ID: 27870947
[TBL] [Abstract][Full Text] [Related]
9. Wild-type FLT3 and FLT3 ITD exhibit similar ligand-induced internalization characteristics.
Kellner F; Keil A; Schindler K; Tschongov T; Hünninger K; Loercher H; Rhein P; Böhmer SA; Böhmer FD; Müller JP
J Cell Mol Med; 2020 Apr; 24(8):4668-4676. PubMed ID: 32155324
[TBL] [Abstract][Full Text] [Related]
10. Leukemogenic potency of the novel FLT3-N676K mutant.
Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
[TBL] [Abstract][Full Text] [Related]
11. Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction.
Tickenbrock L; Schwäble J; Wiedehage M; Steffen B; Sargin B; Choudhary C; Brandts C; Berdel WE; Müller-Tidow C; Serve H
Blood; 2005 May; 105(9):3699-706. PubMed ID: 15650056
[TBL] [Abstract][Full Text] [Related]
12. Features of Ras activation by a mislocalized oncogenic tyrosine kinase: FLT3 ITD signals through K-Ras at the plasma membrane of acute myeloid leukemia cells.
Köthe S; Müller JP; Böhmer SA; Tschongov T; Fricke M; Koch S; Thiede C; Requardt RP; Rubio I; Böhmer FD
J Cell Sci; 2013 Oct; 126(Pt 20):4746-55. PubMed ID: 23943874
[TBL] [Abstract][Full Text] [Related]
13. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel WE; Serve H
Blood; 2000 Dec; 96(12):3907-14. PubMed ID: 11090077
[TBL] [Abstract][Full Text] [Related]
14. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
[TBL] [Abstract][Full Text] [Related]
15. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.
Brandts CH; Sargin B; Rode M; Biermann C; Lindtner B; Schwäble J; Buerger H; Müller-Tidow C; Choudhary C; McMahon M; Berdel WE; Serve H
Cancer Res; 2005 Nov; 65(21):9643-50. PubMed ID: 16266983
[TBL] [Abstract][Full Text] [Related]
16. Internal tandem duplication of FLT3 deregulates proliferation and differentiation and confers resistance to the FLT3 inhibitor AC220 by Up-regulating RUNX1 expression in hematopoietic cells.
Hirade T; Abe M; Onishi C; Taketani T; Yamaguchi S; Fukuda S
Int J Hematol; 2016 Jan; 103(1):95-106. PubMed ID: 26590920
[TBL] [Abstract][Full Text] [Related]
17. High fms-like tyrosine kinase-3 (FLT3) receptor surface expression predicts poor outcome in
Sharawat SK; Raina V; Kumar L; Sharma A; Bakhshi R; Vishnubhatla S; Gupta R; Bakhshi S
Indian J Med Res; 2016 May; 143(Supplement):S11-S16. PubMed ID: 27748272
[TBL] [Abstract][Full Text] [Related]
18. Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling.
Xu Y; Wang P; Li M; Wu Z; Li X; Shen J; Xu R
Biomed Pharmacother; 2021 Jan; 133():111054. PubMed ID: 33254022
[TBL] [Abstract][Full Text] [Related]
19. Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation.
Kresinsky A; Schnöder TM; Jacobsen ID; Rauner M; Hofbauer LC; Ast V; König R; Hoffmann B; Svensson CM; Figge MT; Hilger I; Heidel FH; Böhmer FD; Müller JP
Oncogene; 2019 Jun; 38(24):4773-4787. PubMed ID: 30820040
[TBL] [Abstract][Full Text] [Related]
20. Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD.
Okamoto M; Hayakawa F; Miyata Y; Watamoto K; Emi N; Abe A; Kiyoi H; Towatari M; Naoe T
Leukemia; 2007 Mar; 21(3):403-10. PubMed ID: 17230226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
